Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

U.S. Genomics Announces New Chief Executive Officer

Published: Friday, December 16, 2005
Last Updated: Friday, December 16, 2005
Bookmark and Share
John J. Canepa has been promoted to President, CEO and member of the Board of Directors.

U.S. Genomics has announced that John J. Canepa has been promoted to President, Chief Executive Officer and member of the Board of Directors.

"John's business acumen, combined with his extensive experience in the life sciences, represents an unparalleled set of qualifications to lead this company through its commercialization efforts and the next phase of its biodefense contract," said Gus Lawlor, Managing Director at HealthCare Ventures and a U.S. Genomics board member.

"We are excited to move forward in this next phase of biodefense development and commercialization of the single molecule biology technology under John's leadership."

Canepa originally joined U.S. Genomics as Chief Financial Officer. During his tenure as CFO, Canepa saw the Company through the development and launch of the Trilogy® 2020 platform and Direct™ miRNA assays and through two phases of a multi-million-dollar biodefense contract with the U.S. Department of Homeland Security.

Prior to joining U.S. Genomics, Canepa served as Vice President, Finance & Administration, and Chief Financial Officer of Winphoria Networks, Inc., a venture capital-backed telecommunications company.

Previously he was a senior partner in the Boston office of Arthur Andersen, where he led the firm's worldwide life sciences practice.

Canepa holds a Masters in Finance from Michigan State University and a B.A. from Denison University.

"U.S. Genomics has made great strides with its biodefense work and this is an especially exciting time to be part of this company," said Canepa.

"It is a privilege to lead such a dynamic team in both the biodefense applications and the development of the Trilogy 2020 platform and assays."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

U.S. Genomics Announces Recipient of Outstanding Investigator in Single Molecule Biology Award
Dr. James A. Spudich will be presented the award at the 50th Annual Meeting of the Biophysical Society.
Tuesday, February 21, 2006
NSF Awards U.S. Genomics a $500K Phase II-B SBIR Grant
The $500,000 grant is earmarked for development of a commercial platform that uses the Company's rapid DNA analysis and genomic mapping technologies.
Friday, October 07, 2005
U.S. Genomics Expands its Efforts With New VP
U.S. Genomics Names Duncan Whitney as Vice President of Research and Development.
Friday, September 30, 2005
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!